Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (107)	9/18/1998 3:14:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1073

Rick, How about entering -2000 (or whatever the number is) as the number of "$" held to reflect the accumulated loss/profit? Peter

To: scaram(o)uche who wrote (107)	9/18/1998 6:00:00 PM
From: JOEBT1	Read Replies (2) \| Respond to of 1073

Richard--I recommend adding Imunogen (IMGN) to the portfolio. Human colon cancer induced in mice completely eradicated. Drug has same effect on small lung cancer. 200 day test on induced pancreatic cancer now half way through expected to yield same results. Primate safety tests indicates no major toxicity problems. Long awaited deal with major pharma will happen "soon". A deal has already been made with Biochem Pharma on IMGN's Apoptosis subsidiary. The CEO has an open telephone policy for shareholders. I've talked to Mitch Sayare, the CEO 4 times this year and he says a documented deal pages of 80+ requires a third signature--but he also says no guarantees, of course. Phase I will start for colon cancer in December on cancer patients--so if the drug is " silver bullet" we would know 6 months into '99. Yahoo thread for IMGN very good. Incidentally the Biotech ValueFund made a 3 million investment early this year.